Recombinant Human JAK2 and EPOR Fusion Protein, FLAG/His-tagged

• Cat.No.: JAK2-35H
• Product Overview: Complex of Human JAK2, also known as Janus Kinase 2, with V617F, Y1007F and Y1008F mutations, GenBank Accession No. NM_004972, a.a. 36-1132(end), with N-terminal FLAG-tag, MW=128 kDa, and human EPOR, also known as Erythropoietin receptor, GenBank Accession No. NM_000121, a.a. 273-338 with N-terminal His-tag, MW=9 kDa. The proteins were expressed as single fusion protein with a (GSSG)8 linker in a Baculovirus infected Sf9 cell expression system.

Specification

• Description: This gene encodes a non-receptor tyrosine kinase that plays a central role in cytokine and growth factor signalling. The primary isoform of this protein has an N-terminal FERM domain that is required for erythropoietin receptor association, an SH2 domain that binds STAT transcription factors, a pseudokinase domain and a C-terminal tyrosine kinase domain. Cytokine binding induces autophosphorylation and activation of this kinase. This kinase then recruits and phosphorylates signal transducer and activator of transcription (STAT) proteins. Growth factors like TGF-beta 1 also induce phosphorylation and activation of this kinase and translocation of downstream STAT proteins to the nucleus where they influence gene transcription. Mutations in this gene are associated with numerous inflammatory diseases and malignancies. This gene is a downstream target of the pleiotropic cytokine IL6 that is produced by B cells, T cells, dendritic cells and macrophages to produce an immune response or inflammation. Disregulation of the IL6/JAK2/STAT3 signalling pathways produces increased cellular proliferation and myeloproliferative neoplasms of hematopoietic stem cells. A nonsynonymous mutation in the pseudokinase domain of this gene disrupts the domains inhibitory effect and results in constitutive tyrosine phosphorylation activity and hypersensitivity to cytokine signalling. This gene and the IL6/JAK2/STAT3 signalling pathway is a therapeutic target for the treatment of excessive inflammatory responses to viral infections. Alternative splicing results in multiple transcript variants encoding distinct isoforms.
• Source: Insect cell
• Species: Human
• Tag: JAK2: N-terminal FLAG-tag
  EPOR: N-terminal His-tag
• Form: Aqueous buffer solution
• Molecular Mass: JAK2: 128 kDa, EPOR: 9 kDa
• Protein length: JAK2: 26-1132(end), EPOR: 273-338
• Purity: 87%
• Storage: At least 6 months at –80 centigrade.
• Storage Buffer: 50 mM Tris-HCl, pH 8.0, 500 mM NaCl, 10% glycerol, 3 mM DTT.

Gene Information

• Gene Name: JAK2 Janus kinase 2 [ Homo sapiens (human) ]
• Official Symbol: JAK2
• Synonyms: JAK2; Janus kinase 2; JTK10; tyrosine-protein kinase JAK2; JAK-2; Janus kinase 2 (a protein tyrosine kinase); EC 2.7.10.2; jak; jh1
• Gene ID: 3717
• mRNA Refseq: NM_004972
• Protein Refseq: NP_004963
• MIM: 147796
• UniProt ID: O60674

Reviews

10/03/2020

Quick response from customer service.

05/12/2020

Product performed as expected.

08/07/2018

Satisfied with product quality.

Q&As

What role does JAK2 play in myeloproliferative neoplasms (MPNs)?

JAK2 mutations, particularly JAK2 V617F, are hallmarks of several MPNs, including polycythemia vera, essential thrombocythemia, and primary myelofibrosis. These mutations lead to uncontrolled cell proliferation.

How does JAK2 activation lead to downstream signal transduction?

Upon cytokine binding to its receptor, JAK2 becomes activated through phosphorylation. This activation leads to the phosphorylation and activation of STAT (Signal Transducers and Activators of Transcription) proteins, which then translocate to the nucleus and regulate gene expression.

What is the primary function of the JAK2 protein in cellular signaling?

JAK2 is a non-receptor tyrosine kinase that plays a pivotal role in cytokine signaling, mediating cellular responses to growth factors and various cytokines.

How is JAK2 involved in hematopoiesis and blood cell development?

JAK2 is crucial for hematopoiesis, especially in the signaling pathways of erythropoietin and thrombopoietin, which are essential for red blood cell and platelet production, respectively.

How does JAK2 interact with cytokine receptors, and what is its significance?

JAK2 associates with the intracellular domains of specific cytokine receptors. Upon cytokine binding, JAK2 becomes activated, leading to downstream signaling events. This interaction is vital for mediating cellular responses to various cytokines.

Are there therapeutic agents that target JAK2, and in what contexts are they used?

Yes, there are several JAK2 inhibitors, such as ruxolitinib and fedratinib, which are used to treat MPNs. They work by inhibiting the kinase activity of JAK2, thereby reducing aberrant cell proliferation.

Are there known mutations in the JAK2 gene, and what are their implications?

Yes, one of the most well-known mutations is JAK2 V617F, which results in constitutive activation of the kinase. This mutation is associated with various myeloproliferative neoplasms (MPNs).